Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Zydus Lifesciences subsidiary has partnered with Zhuhai Beihai Biotech to market a cancer drug, Beizray (Albumin Solubilized ...

UK MHRA grants marketing authorization to Telix’s prostate cancer PET imaging agent, Illuccix: Melbourne, Australia Friday, February 14, 2025, 10:00 Hrs [IST] Telix, a commercia ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare ...

Gozetotide binds to the cancer cells with prostate-specific membrane antigen (PSMA) on their surface, making them visible ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

Telix Pharmaceuticals Limited today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been approved by the Danish ...